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A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities and the response rate of carboplatin
and 5-fluorouracil administered daily with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung
cancer. In a phase I/II clinical trial, patients with histologically documented, unresectable stage IIIA or IIIB non-small-cell lung cancer
(NSCLC) were enrolled. Carboplatin (20–40mgm
2 2-h infusion, daily) and 5-fluorouracil (200mgm
2 24-h continuous infusion,
daily) were administered concurrently with radiotherapy on days 1–33. Radiotherapy, with a total dose of 60Gy, was delivered in 30
fractions on days 1–40. In the phase I portion, the daily dose of carboplatin was escalated from 20 to 40mgm
2. Once the maximum
tolerated dose (MTD) and recommended dose (RD) of carboplatin was determined, the study entered the phase II portion. In the
phase I portion, the daily MTD and RD of carboplatin were 40 and 35mgm
2, respectively. The dose-limiting toxicity was
neutropenia. In the following phase II study, 30 patients were entered and the objective response rate was 76.7% (95% CI, 62–92%)
and the local control rate was 85.7%. The median survival time was 19.8 months, with a survival rate of 70% at 1 year, 36.7% at 2
years. The major toxicities of treatment were neutropenia (Xgrade 3, 87.9%) and thrombocytopenia (Xgrade 3, 23.3%). This
combined therapy for locally advanced non-small-cell lung cancer is promising and shows acceptable toxicity.
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Non-small-cell lung cancer (NSCLC) accounts for approximately
75% of all lung cancers (Travis et al, 1995). Only a low percentage
of patients present a disease susceptible to surgical resection. In
fact, approximately 40% of patients with NSCLC present with
locally or regionally advanced tumours that are ineffectively
treated by primary surgery. Large studies have shown that a small
percentage of those patients can be cured with radiotherapy and
even after using the best available radiation schedules, recurrences
in the radiation field are observed in a substantial percentage of
the patients (Cox et al, 1990; Arriagada et al, 1991; Graham et al,
1995).
Due to the limited benefits provided by radiation therapy alone,
the use of combined chemoradiotherapy in the patients has been
explored. A combination of chemotherapy and radiotherapy has
been shown to improve the outcome of the patients with locally
advanced NSCLC, achieving a median survival of 13–14 months
and 5-year survival rates of 13–20% (Dillman et al, 1990, 1996;
Schaake-Koning et al, 1992; Sause et al, 1995).
In the EORTC phase III study, 08844 Schaake-koning et al
(1992) demonstrated that radiotherapy combined with daily
administration of low-dose cisplatin resulted in improved local
control and actuarial survival in patients with unresectable NSCLC.
In that study, daily administration of cisplatin proved to be more
effective than a weekly schedule in potentiating the local tumour
control achievable with radiation alone. In addition, Jeremic et al
(1996) reported that the combination of radiation therapy and low-
dose daily carboplatin (CBDCA) plus etoposide improved the
survival of patients with stage III NSCLC as a result of improved
local control. These results suggest that concurrent low-dose daily
administration of platinum compounds enhance local control by
radiation therapy, resulting in better survival of stage III NSCLC.
Many agents have been reported to have a radiosensitising
effect. 5-fluorouracil (5-FU) was demonstrated to be a radio-
sensitiser in a preclinical study (Byfield et al, 1982). A randomised
study using single-agent 5-FU in conjunction with radiotherapy
suggested that, in terms of local control and patient survival, it
improved the effect of radiotherapy alone (Lo et al, 1976).
Although inhibition of repair of radiation-induced DNA damage
has been postulated to occur, the precise cellular mechanisms by
which 5-FU and radiotherapy interact have not been defined
(Schilsky, 1992).
In addition to the raidosensitising effect of these agents, a
combination of platinum compound and 5-FU has been shown to
have synergistic antitumour activity in both preclinical and clinical
studies (Scanlon et al, 1986; Olver et al, 1989; Esaki et al, 1992;
Saikawa et al, 1994). The mechanism of synergism of these two
agents remains unclear, although there are various hypotheses
concerning the modulatory effect of platinum compounds on
5-FU. It was suggested that the platinum-induced intracellular
folate level potentiates the effect of 5-fluorodeoxyuridine Received 3 January 2003; revised 9 May 2003; accepted 29 June 2003
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lmonophosphate by forming a covalent ternary complex with
thymidylate synthase, leading to enhanced 5-FU cytotoxicity
(Scanlon et al, 1986).
These results prompted us to conduct a phase I–II trial of
carboplatin and continuous infusion of 5-FU in combination with
concurrent radiotherapy in patients with locally advanced NSCLC.
The objective of the trial was to determine the maximum tolerated
dose of carboplatin that could be used in combination with
continuous infusion of 5-FU and concurrent radiotherapy. The
efficacy and toxicity of the combination were further evaluated in
the following phase II study.
MATERIALS AND METHODS
Patient eligibility
Previously untreated patients with histologically documented
inoperable stage IIIA or stage IIIB NSCLC were eligible for this
study. Patients with a malignant or exudative pleural effusion were
not eligible. All patients had measurable or assessable disease.
Further eligibility criteria included: age greater than 20 and less
than 75 years; ECOG performance status p2; no prior chemother-
apy; no prior lung radiation therapy; platelet count X100000ml
1;
white blood cell (WBC) count 3000ml
1; haemoglobin 410gdl
1;
BUN o1.5-fold the upper limit of normal (ULN); creatinine level
o1.1mgdl
1; bilirubin o1.5-fold the upper limit of normal
(ULN); AST otwo-fold the ULN; 24-h creatinine clearance
X60mlmin
1; PaO2465mmHg in a sample of arterial blood;
and no other serious medical or psychiatric illness. Height, weight,
performance status and tumour stage were recorded. Before
initiation of protocol therapy, all patients underwent a history
and physical examination; complete blood cell count (CBC) with
differential and platelet count; chemistry panel; posterior–anterior
(PA) and lateral chest radiography; computed tomographic (CT)
scan of the head, chest, and upper abdomen (to include the liver
and adrenals); and a bone scan. The protocol was approved by the
Institutional Ethics Board. All patients gave written informed
consent.
Chemotherapy
Carboplatin (20–40mgm
2 2-h infusion), and 5-FU (200mgm
2
24-h continuous infusion) were administered concurrently with
radiotherapy on days 1–33 (Figure 1). Carboplatin was adminis-
tered as a 2-h intravenous infusion 1–2h before irradiation. The
daily dose of carboplatin was increased stepwise from 20 to
40mgm
2 in 5mg increments. 5-FU (200mgm
2) was adminis-
terd as a 24-h continuous infusion. When grade 3 or higher
haematological toxicity occurred, chemotherapy was withheld
until toxicity recovered to pgrade 2.
Radiation therapy
Chest irradiation was started concurrently on day 1 for all patients
using a linear accelerator (6–10MeV). A total dose of 60Gy was
delivered in 30 fractions at five fractions per week over 6 weeks.
The treatment volumes consisted of original and boost volumes.
The initial dose of 40Gy was administered to the original
volume, which included the site of the primary tumour
with a margin of 2cm around the mass and the ipsilateral
hilum, and the whole width of the mediastinum with a margin of
1cm around the radiographically demonstrated tumour mass.
The supraclavicular region was further included if involved with
the tumour. An additional 20Gy was administered to the boost
volume that included the site of the primary tumour and involved
lymph nodes. The original volume was treated with an anterior–
posterior parallel–opposed pair of portals, and the boost volume
was treated with the same pair or with a pair of oblique fields if the
cumulative radiation dose to the spinal cord was greater than
45Gy.
When grade 3 or higher radiation esophagitis toxicity or grade 4
haematological toxicity occurred, radiation therapy was withheld
until those toxicities recovered to pgrade 2.
Toxicity and response evaluation
Toxicity was graded using the WHO scale for acute and subacute
toxicity. The radiation-induced effect on normal tissue was
assessed as either acute or late toxicity, according to the RTOG/
EORTC criteria (Cox et al, 1995). A minimum of three patients
were evaluated per dose level. The maximum-tolerated dose
(MTD) was defined as the dose level that produced grade 4
myelosuppression (X4 days) and grade 3–4 nonhaematologic
toxicity (excluding alopecia) in two-thirds of the patients. If none
of the three patients experienced dose-limiting toxicity (DLT), the
subsequent patients were treated at the next dose level. If one of
the three patients experienced DLT, more patients were entered at
the same dose level. Complete blood cell count measurement was
performed at least twice weekly, while routine chemistry, urine
analysis and chest X-rays were performed once per week during
chemotherapy.
The standard response criteria used were as follows: complete
response (CR) was defined as the disappearance of all measurable
disease and complete disappearance of all signs, symptoms and
biochemical evidence of tumour activity for at least 4 weeks; partial
response (PR) was defined as a 50% or greater decrease in the
product of the perpendicular measurements of disease with no
progression in any lesion and no new lesions identified; no change
(NC) was defined as no evidence of progressive disease or any
measurable response less than a PR; progressive disease (PD) was
defined as a greater than 25% increase in the product of the longest
perpendicular diameters of any measurable lesion or the
appearance of new lesions.
Days
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Carboplatin
5-fluorouracil
Chest radiation 2 Gy
(total dose 60 Gy)
Figure 1 Treatment schema for daily carboplatin, 5-FU and concurrent radiation therapy.
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lStatistical analysis
The phase II part of this study was designed to detect a response
rate of 75% compared with a minimal, clinically meaningful
response rate of 50%. A sample size of 30 patients was required
with an a error of 0.1 and b error of 0.1. Survival analysis was
performed using the Kaplan–Meier method (Fleming, 1982).
RESULTS
Patient characteristics
The patient characteristics are listed in Table 1. Forty-six patients
(26 with IIIA, 20 with IIIB) were entered into the study between
February 1995 and March 1999. In all, 42 were male and four were
female patients; the median age was 59.5 years (range, 39–71). The
ECOG PS was as follows: 12 patients of PS 0, 34 patients of PS 1.
In total, 22 patients were treated in the phase I portion of the
study: three patients at the carboplatin dose level of
20mgm
2day
1, three patients at 25mgm
2day
1, four at
30mgm
2day
1, six at 35mgm
2day
1 and six at
40mgm
2day
1. After the determination of the MTD and
recommended dose (RD) of daily carboplatin, 24 patients were
entered into the phase II part of the trial.
Toxicity and MTD determination
Toxicity was evaluated for all eligible patients. The recommended
dose of daily carboplatin was deemed to be 35mgm
2 because at
40mgm
2, four of the six patients experienced DLT as defined by
the protocol; grade 4 neutropenia persisted for over 4 days
(Table 2). Grade 3 thrombocytopenia was frequently observed at
level 5 (carboplatin dose 40mgm
2) and three cases required to
infuse platelet concentrates. Grades 1–2 oesophagitis was observed
at all dose levels. In a subsequent phase II study, 30 patients
including six patients treated at the RD in the phase I study were
entered. Haematological and nonhaematological toxicities of the
study are listed in Table 3. Neutropenia was the most severe
toxicity noted in this study. Three patients (10%) had grade 4
neutropenia which persisted for 3–5 days (mean 4 days), and both
chemotherapy and radiation therapy were interrupted for 4–7
days (mean 5.7 days). These patients underwent rhG-CSF
administration. Among them, one patient experienced grade 2
fever and all the patients experienced grade 1–2 oesophagitis,
except one case who had grade 3 at a final week of radiation
therapy. Two patients had grade 3 acute pulmonary toxicity and
required a transient oxygen supply. Due to this acute toxic effect,
irradation was interrupted for 7 and 16 days. Grade 2 late toxicity
(RTOG) was observed in two patients who had symptomatic
radiation pulmonary fibrosis.
Response and survival
Of the 30 evaluable patients in the phase II part of the study, two
patients (6.7%) achieved a CR and 21 (70%) achieved a PR for an
overall response rate of 76.7% (95% CI, 62–92%). Local control
was achieved in 85.7% of the patients and distant metastasis was
the reason for treatment failure of all three cases evaluated as PD.
The 1-year overall survival rate was 70% and the 2-year survival
rate was 36.7% (Figure 2). The median overall survival time and
median follow-up time was 19.8, and 25.8 months, respectively.
The median progression-free survival time was 11.1 months.
Pattern of failure
In all, 15 of 23 responding patients had relapsed. The median time
to progression of responding patients was 13.9 months. Distant
metastases alone were the primary site of disease progression in
seven (47%) patients, three (20%) developed locoregional only
progression and five (33%) developed both distant metastases and
locoregional progression. Of the patients with distant metastases,
the brain was the most common site of failure with three (25%)
patients presenting with brain-only metastases, three (33%) with
brain and bone metastases and two (17%) with brain and adrenal
gland metastases. Two patients developed metastases in the
adrenal gland alone and the remaining two patients presented
with liver metastases alone.
DISCUSSION
Approximately 40% of patients with newly diagnosed NSCLC
initially present with locally advanced disease, and the majority are
inoperable. Thoracic radiation therapy (TRT) provides local
control and effective palliation of symptoms, but has minimal
effect on survival for this set of patients. The addition of
chemotherapy to TRT sequentially (Dillman et al, 1990; Le
Chevalier et al, 1992; Sause et al, 1995) or concurrently (Jeremic
et al, 1995, 1996; Schaake-Koning et al, 1992) has shown an impact
on survival among patients with unresectable NSCLC, especially
those with good performance status and o5% weight loss (Sause
Table 1 Patient characteristics
Characteristic No. of patients(%)
No. of patients entered 46
No. of patients eligible 46
Gender
Male 42 (91.3)
Female 4 (8.7)
ECOG performance status
0 12 (26.1)
1 34 (73.9)
20
Histology
Squamous cell carcinoma 24 (52.2)
Adenocarcinoma 22 (47.8)
Stage of disease
IIIA 26 (56.5)
IIIB 20 (43.5)
Table 2 Haematological and nonhaematological toxicity in the phase I study
Neutropenia Thrombocytopenia Oesophagitis Pneumonitis
Carboplatin dose level (mgm
2) No. of patients Grade 3 Grade 4 Grade 3 Grade 4 Grade 2 Grade 3 Grade 2 Grade 3
2 0 3 1 00 00 0 0 0
2 5 3 2 01 01 0 0 0
3 0 4 2 01 00 0 0 0
3 5 6 4 24 00 0 0 0
4 0 6 2 44 02 0 0 0
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let al, 1995), compared with TRT alone. Recent progress in the
management of locally advanced NSCLC came about in part
because of the recognition that cisplatin-based chemotherapy
imparts a modest but real survival benefit in this set of patients.
With a newer combination of chemotherapy regimens containing
vinorelbin, gemcitabine or paclitaxel, additional albeit modest
survival gains have been realised in recent years. Thus, the survival
of patients with locally advanced, unresectable NSCLC has
improved in part because of more active chemotherapy regimens.
However, improving local tumour control is a key factor for
optimising survival. Efforts to improve local tumour control are
apparently worthwhile because enhanced local control can
translate into improved survival even in the absence of improved
control of extrathoracic metastases (Perez et al, 1986; Schaake-
Koning et al, 1992; Jeremic et al, 1996; Saunders et al, 1999). The
strategies designed to improve local control include (a) the use of
radiation-sensitising drugs, (b) the use of fractionation of
radiations and (c) escalated radiation doses with three-dimen-
sional (3-D) treatment planning.
Regarding radiation-sensitising drugs, several common anti-
neoplastic agents such as cisplatin, etoposide, paclitaxel and
gemcitabine among others have the potential to act as radiation-
sensitising agents. Although newer drug regimens combined with
radiotherapy can be expected to improve the clinical outcome
further, increased host toxicities may cause the interruption of the
treatment or dose reduction of one or both treatment modalities
(Yokoyama et al, 1998; Blackstock et al, 2001).
We designed this phase I/II study in an attempt to improve local
tumour control, which had been shown to affect the survival of
patients with stage III NSCLC. Both carboplatin and 5-FU selected
for the current study were demonstrated to be radiosensitisers in
preclinical (Byfield et al, 1982; Begg et al, 1987; Havemann et al,
1992) and clinical studies (Lo et al, 1976; Wolf et al, 1992; Belani
and Aisner, 1994; Belani et al, 1996). In addition, a combination of
platinum compound and 5-FU was shown to have synergistic
antitumour activity (Scanlon et al, 1986; Olver et al, 1989; Esaki
et al, 1992; Saikawa et al, 1994). In the phase I part of the current
study, the recommended dose of daily carboplatin was determined
to be 35mgm
2 because at 40mgm
2, patients experienced grade
4 neutropenia and/or grade 3 thrombocytopenia. The dose of 5-FU
(200mgm
2) was determined according to the previous trials that
were aimed to improve local control by radiation therapy (Hansen
et al, 1987; Ngan et al, 2001; Nishimura et al, 2002).
In contrast to the haematological toxicities, severe radiation
oesophagitis was not observed at any dose levels. In a subsequent
phase II study, two patients (6.7%) achieved a CR and 21 (70%)
achieved a PR for an overall response rate of 76.7%. Local control
was achieved in 85.7% of patients, and distant metastasis was the
reason for treatment failure in all three cases evaluated as PD. In
addition, the primary tumour of two cases evaluated as no change
continued to reduce their size for several months and these cases
were re-evaluated as PR. Including these cases, local control was
achieved in 93.3% patients, which is favourable compared with
previous findings.
Although the current study focused on the local control, the
distinct goal of locally advanced NSCLC is preventing distant
failure. In the trial of sequential full-dose chemotherapy by Le
Chevalier et al (1994), the improved survival seen in the combined-
modality arm was related entirely to a decrease in distant failure.
In addition, the Southwest Oncology Group trial 9504 evaluated
docetaxel as a consolidation therapy following concurrent
chemoradiotherapy in stage III NSCLC. The results in 83 patients
showed prolonged survival (median survival 26 months, 1-year
survival 76% and 2-year survival 53%), the best results reported to
date (Gandara et al, 2000). Based on the present results, a phase II
trial that evaluates the feasibility and the efficacy of consolidation
therapy following the current chemoradiotherapy is ongoing in our
study group.
In conclusion, a combination of daily carboplatin and 5-FU with
concurrent thoracic radiotherapy was found to be effective and
feasible for the treatment of locally advanced NSCLC. Although the
response rate and median survival were favourable compared with
previously published phase II studies, additional consolidation
chemotherapy to control distant micrometastasis needs to be
considered to improve the clinical outcome further.
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